AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaTechnology, Industry, AgricultureInformation ScienceNamed GroupsHealth CareGeographicals
Influenza VaccinesInfluenza, HumanInfluenza A virusInfluenza A Virus, H1N1 SubtypeVaccines, InactivatedInfluenza B virusInfluenza A Virus, H3N2 SubtypeImmunosuppressionInfluenza in BirdsInfluenza A Virus, H5N1 SubtypeVaccinesVaccinationHemagglutination Inhibition TestsHemagglutinin Glycoproteins, Influenza VirusAntibodies, ViralOrthomyxoviridae InfectionsOrthomyxoviridaePandemicsViral VaccinesPolysorbatesVaccines, SyntheticVaccines, CombinedVaccines, SubunitSqualeneVaccines, DNAVaccines, AttenuatedCross ProtectionBacterial VaccinesSeasonsAdjuvants, ImmunologicInfluenza A Virus, H9N2 SubtypeInfluenza A Virus, H2N2 SubtypeInfluenza A Virus, H3N8 SubtypeImmunosuppressive AgentsAdministration, IntranasalAIDS VaccinesVaccines, VirosomeDisease OutbreaksNeuraminidaseImmunization ScheduleInjections, IntradermalVaccines, ConjugateInjections, IntramuscularHemagglutinins, ViralAntibody FormationImmunization ProgramsMice, Inbred BALB CImmunization, SecondaryReassortant VirusesAntibodies, NeutralizingUnited StatesTechnology TransferMalaria VaccinesImmunity, HumoralImmunizationMass VaccinationTechnology, PharmaceuticalTime FactorsPapillomavirus VaccinesInfluenza A Virus, H7N9 SubtypeImmune ToleranceSentinel SurveillanceAntigens, ViralFerretsCross ReactionsMeningococcal VaccinesOseltamivirInfluenza A Virus, H7N7 SubtypeGraft RejectionBirdsHemagglutininsMadin Darby Canine Kidney CellsTreatment OutcomeInfluenzavirus BTacrolimusHepatitis B VaccinesKidney TransplantationInfluenza A Virus, H5N2 SubtypeNeutralization TestsAntiviral AgentsVirus SheddingImmunocompromised HostImmunoglobulin GInfluenzavirus AMeasles VaccineVaccines, Virus-Like ParticleImmunity, CellularPertussis VaccineBCG VaccineHaemophilus VaccinesDogsDrug-Related Side Effects and Adverse ReactionsCyclosporinePopulation SurveillanceRisk FactorsPoliovirus Vaccine, InactivatedRabies VaccinesT-LymphocytesProspective StudiesRotavirus Vaccines
H1N1Antiviral agentsAdultsHospitalizationEpidemicsStrainsVirusesPneumococcalMRNA-based vaccinesAbrupt onset of feverPandemicEfficacyBioNTech and ModernaComplicationsImpact of influenzaSecondary bacterial pneumonia2023ImmunizationIllnessAvian influenzaPatients with solid tumorsSystemicDoseEffectivenessAntibodiesSeasonalModernaMeningococcalAntigenicVaccination historySubtypesHepatitisImmunityImmunogenicityClinicalInfectionPreventionSeverity2019FeverDosesRecommendationsImmune responseIllnessesVector-basedOccurs
H1N111
  • We conducted a population-based study in Manitoba, Canada, to investigate whether use of inactivated trivalent influenza vaccine (TIV) during the 2008-09 influenza season was associated with subsequent infection with influenza A(H1N1)pdm09 virus during the first wave of the 2009 pandemic. (cdc.gov)
  • The test-negative case-control study included 831 case-patients with confirmed influenza A(H1N1)pdm09 virus infection and 2,479 controls, participants with test results negative for influenza A and B viruses. (cdc.gov)
  • For the association of TIV receipt with influenza A(H1N1)pdm09 virus infection, the fully adjusted odds ratio was 1.0 (95% CI 0.7-1.4). (cdc.gov)
  • In agreement with study findings outside Canada, our study in Manitoba indicates that the 2008-09 TIV neither increased nor decreased the risk for infection with influenza A(H1N1)pdm09 virus. (cdc.gov)
  • The nature of the relationship between receipt of the 2008-09 seasonal inactivated trivalent influenza vaccine (TIV) and the risk for infection with the pandemic (H1N1) 2009 virus strain, hereafter referred to as A(H1N1)pdm09, remains unclear. (cdc.gov)
  • In addition, 3 other studies conducted by the same team found a 1.4- to 2.5-fold increased risk for infection (laboratory confirmed) with influenza A(H1N1)pdm09 virus among persons who received the 2008-09 TIV ( 1 ). (cdc.gov)
  • The two influenza A virus subtypes have cocirculated in human populations since 1977: influenza A (H1N1) and A (H3N2). (cdc.gov)
  • Reassortment between influenza A (H1N1) and A (H3N2) viruses resulted in the circulation of A (H1N2) virus during the 2001-02 and 2002-03 influenza seasons. (cdc.gov)
  • In April 2009, a novel influenza A (H1N1) virus, influenza A(H1N1)pdm09-which was different from currently circulating influenza A (H1N1) viruses-emerged and its subsequent spread resulted in the first pandemic of the 21st century. (cdc.gov)
  • Influenza A viruses have predominated overall, with both influenza A(H1N1) and A(H3N2) circulating. (canada.ca)
  • Subtypes which have in the past caused pandemics include the influenza A H1N1, H2N2, H3N2 and H1N1pdm09 viruses, while the H3N2 and H1N1pdm09 viruses continue to cause epidemics as seasonal influenza viruses. (health.govt.nz)
Antiviral agents4
Adults12
  • BACKGROUND: Data are limited about influenza vaccine effectiveness (VE) in the prevention of influenza-related hospitalizations in older adults and those with underlying high-risk comorbidities. (bvsalud.org)
  • METHODS: We conducted a prospective test-negative case-control study at two US hospitals from October 2018-March 2020 among adults ≥50 years of age hospitalized with acute respiratory illnesses (ARIs) and adults ≥18 years admitted with congestive heart failure (CHF) or chronic obstructive pulmonary disease (COPD) exacerbations. (bvsalud.org)
  • Adjusted VE against influenza-related hospitalization for ARI in adults ≥50 years was 55.9% (29.9, 72.3) and adjusted VE against Influenza-related CHF/COPD exacerbation in adults ≥18 years was 80.3% (36.3, 93.9). (bvsalud.org)
  • CONCLUSIONS: Influenza vaccination was effective in preventing influenza-related hospitalizations in adults ≥50 years of age and those with CHF/COPD exacerbations during the 2018-2020 seasons. (bvsalud.org)
  • Adults spread influenza to others during a period from 1 day before symptom onset to up to 7 days afterwards. (canada.ca)
  • Vaccination is associated with reductions in influenza-related respiratory illness and physician visits among all age groups, hospitalization and death among persons at high risk, otitis media among children, and work absenteeism among adults ( 8--18 ). (cdc.gov)
  • Previously healthy children and younger adults also may require hospitalization for influenza-related complications, but the relative increase in their hospitalization rates during epidemics is less than for persons who belong to high-risk groups. (cdc.gov)
  • Children aged under 5 years are more likely than older children or adults to have a febrile reaction to influenza vaccine. (health.govt.nz)
  • All adults and adolescents should get the COVID-19 vaccine regardless of their CD4 count or HIV viral load. (hiv.gov)
  • METHODS: Among adults (≥18 years) hospitalized with laboratory-confirmed, acute COVID-19 between 11 March 2021, and 31 August 2022 at 21 hospitals in 18 states, those hospitalized during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron-predominant period (BA.1, BA.2, BA.4/BA.5) were compared to those from earlier Alpha- and Delta-predominant periods. (bvsalud.org)
  • METHODS: Adults aged ≥18 years who were hospitalized with COVID-like illness at 21 hospitals in 18 U.S. states participating in the IVY Network during February 1-August 31, 2022, were enrolled. (bvsalud.org)
  • HBoV is rarely detected in adults except in cases of immunosuppression [10, 16, 17]. (datexis.com)
Hospitalization7
  • After adjustment for age, race/ethnicity, immunosuppression, month, and season, pooled VE for any influenza-related hospitalization in the eligible study population was 63.1% (95% CI: 43.8, 75.8). (bvsalud.org)
  • Persons 65 years of age and older, young children, pregnant women, and persons of any age with certain underlying health problems are at increased risk for complications of influenza and hospitalization. (cdc.gov)
  • [ 2 ] Early antiviral therapy must be considered among hospitalized children diagnosed with or suspected to have influenza, especially if they have risk factors such as asthma, cardiac problems, or other conditions, to prevent severe complications and prolonged hospitalization. (medscape.com)
  • The principal changes include a) information about the influenza virus strains included in the trivalent vaccine for 1998-99, b) more detailed information about influenza-associated rates of hospitalization, and c) updated information on the possible relationship between Guillain-Barre syndrome and influenza vaccination. (cdc.gov)
  • If they become ill with influenza, such members of high-risk groups (see Groups at Increased Risk for Influenza-Related Complications) are more likely than the general population to require hospitalization. (cdc.gov)
  • We compared the effects of various spike (S) protein mutations in SARS-CoV-2 and its VOC on transmissibility, illness severity, hospitalization risk, fatality rate, immunological evasion, and vaccine efficacy in this review. (infezmed.it)
  • Effectiveness of mRNA COVID-19 vaccines against COVID-19-associated hospitalization was estimated using multivariable logistic regression models to compare the odds of COVID-19 vaccination between SARS-CoV-2-positive case-patients and SARS-CoV-2-negative control-patients. (bvsalud.org)
Epidemics7
  • The sharp rise in influenza-associated acute respiratory illnesses that occurs during annual seasonal epidemics results in increased numbers of visits to physicians' offices, walk-in clinics, and emergency departments. (cdc.gov)
  • Influenza viruses can be divided into 4 types: A, B, C, and D. Influenza type C viruses are not associated with severe disease, epidemics, or pandemics, and influenza D viruses primarily affect cattle and are not known to infect or cause illness in people, so neither will be discussed further here. (cdc.gov)
  • For these reasons, major epidemics of respiratory disease caused by new variants of influenza continue to occur. (canada.ca)
  • Epidemics of influenza typically occur during the winter months in temperate regions and have been responsible for an average of approximately 36,000 deaths/year in the United States during 1990--1999 ( 1 ). (cdc.gov)
  • During influenza epidemics, high attack rates of acute illness result in both increased numbers of visits to physicians' offices, walk-in clinics, and emergency rooms and increased hospitalizations for management of lower respiratory tract complications. (cdc.gov)
  • Influenza epidemics occur each year. (health.govt.nz)
  • Influenza B has two lineages of viruses: B/Victoria and B/Yamagata, which are also associated with outbreaks and epidemics, and account for a significant proportion of the overall burden of influenza. (health.govt.nz)
Strains6
  • the increased risk might be related to the use of the domestically manufactured vaccine ( 1 ) or to the timing of the pandemic in relation to the most recent influenza season and the types of circulating influenza strains during that season ( 17 , 18 ). (cdc.gov)
  • These were the 3 strains recommended that year by the World Health Organization for influenza vaccines in the Northern and Southern Hemispheres ( 21 ). (cdc.gov)
  • As a result of these antigenic changes, antibodies produced to influenza viruses as a result of infection or vaccination with earlier strains may not be protective against viruses circulating in later years. (cdc.gov)
  • It is active against influenza A and B including strains resistant to neuraminidase inhibitors. (medscape.com)
  • The antigenic characteristics of circulating strains provide the basis for selecting the virus strains included in each year's vaccine. (cdc.gov)
  • Depends on the match of the strains in the vaccine with circulating strains, the age of the individual and whether they have any underlying medical conditions. (health.govt.nz)
Viruses17
  • Influenza is an acute respiratory disease caused by infection with influenza viruses. (cdc.gov)
  • Influenza type A viruses are divided into subtypes based on surface proteins called hemagglutinin (HA) and neuraminidase (NA). (cdc.gov)
  • A few bat species were recently shown to be infected by influenza viruses originally designated as new influenza A subtypes H17N10 and H18N11. (cdc.gov)
  • [8,9] However, these viruses were shown to be incompetent for reassortment with other influenza A viruses, a hallmark of the species, indicating that they are not true influenza A viruses. (cdc.gov)
  • Influenza B viruses are not divided into subtypes, but are further broken down into 2 lineages: Yamagata and Victoria. (cdc.gov)
  • Influenza A and B viruses both undergo gradual, continuous change in the HA and NA proteins, known as antigenic drift. (cdc.gov)
  • Antigenic changes also necessitate frequent updating of influenza vaccine components to ensure that the vaccine is matched to circulating viruses. (cdc.gov)
  • Influenza A viruses are classified into subtypes on the basis of two surface antigens: hemagglutinin (H) and neuraminidase (N). Three subtypes of hemagglutinin (H1, H2 and H3) and two subtypes of neuraminidase (N1 and N2) are recognized among influenza A viruses that have caused widespread human disease. (canada.ca)
  • Although influenza B viruses have shown more antigenic stability than influenza A viruses, antigenic variation does occur. (canada.ca)
  • [ 52 ] The use of adamantanes, such as amantadine, has not been recommended since the 2005-2006 influenza season owing to resistance among influenza A viruses. (medscape.com)
  • Influenza viruses also can cause pandemics, during which rates of illness and death from influenza-related complications can increase worldwide. (cdc.gov)
  • Influenza viruses cause disease among all age groups ( 2--4 ). (cdc.gov)
  • Influenza A and B viruses undergo frequent small changes (mutations) in their segmented RNA genome over time. (health.govt.nz)
  • The new virus subtype has novel H and N surface antigens result from the mixing of genomic segments of two or more influenza A viruses. (health.govt.nz)
  • Other possible mechanisms for the emergence of new influenza viruses are through the adaptation of avian influenza viruses to infect humans and the re-assortment of the genomic segments of multiple viruses (ie, human, avian and pig influenza viruses). (health.govt.nz)
  • molecular diagnostic methods were used for the detection of other respiratory viruses in the other studies whereas we used virus culturing. (datexis.com)
  • BioNTech, Moderna and others like CureVac and Translate Bio aim to use mRNA to design vaccines for viruses like cytomegalovirus, influenza and Zika, as well as in therapies for cancer, immune disorders and diseases of the lungs and metabolism. (biopharmadive.com)
Pneumococcal1
  • Most guidelines for patients with CKD focus on the importance of the hepatitis B, influenza, and pneumococcal vaccines in addition to age-appropriate immunizations. (scienceopen.com)
MRNA-based vaccines1
  • Independent clinical trials demonstrated 94-95% vaccine efficacy against symptomatic disease caused by SARS-CoV-2 for both the Pfizer/BioNTech and Moderna mRNA-based vaccines 3 , 4 . (nature.com)
Abrupt onset of fever2
  • Typical features of influenza include abrupt onset of fever and respiratory symptoms such as cough (usually nonproductive), sore throat, and coryza, as well as systemic symptoms such as headache, muscle aches, and fatigue. (cdc.gov)
  • Typical influenza illness is characterized by abrupt onset of fever, myalgia, sore throat, and nonproductive cough. (cdc.gov)
Pandemic2
  • At the time of the pandemic, the Canadian province of Manitoba was not part of the Canadian vaccine effectiveness monitoring network. (cdc.gov)
  • Although non-pharmaceutical public health interventions have managed to control outbreaks in some countries, most of the global population will depend upon vaccines to mitigate the pandemic. (nature.com)
Efficacy5
  • Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have shown high efficacy, but immunocompromised participants were excluded from controlled clinical trials. (nature.com)
  • Manufacturer(s) have sought approval of the vaccine(s) and provided evidence as to its safety and efficacy only when it is used in accordance with the product monographs. (canada.ca)
  • Therefore, as the efficacy of the novel SARS-CoV-2 vaccines has been proved in clinical trials [ 5 , 6 ], CPs were being prioritized for COVID-19 vaccination. (e-crt.org)
  • Monitoring continues for new variants to enable testing of vaccines and therapies for efficacy. (medscape.com)
  • Due to the politicalization of national immunization, vaccine efficacy and safety has become all but irrelevant. (blogspot.com)
BioNTech and Moderna2
  • On the basis of these data, in December 2020, both the Pfizer/BioNTech and Moderna vaccines were granted emergency use authorization by regulatory agencies in North America. (nature.com)
  • Genetic messenger molecules power the COVID-19 vaccines developed by BioNTech and Moderna, training the body's immune system to detect and defend against disease and infection. (biopharmadive.com)
Complications5
  • Complications of influenza infection include secondary bacterial pneumonia and exacerbation of underlying chronic health conditions. (cdc.gov)
  • Programs should focus on those at high risk of influenza-related complications, those capable of transmitting influenza to individuals at high risk of complications, and those who provide essential community services. (canada.ca)
  • 2 years, and persons of any age who have medical conditions that place them at increased risk for complications from influenza ( 2,5--7 ). (cdc.gov)
  • Influenza vaccination is the primary method for preventing influenza and its severe complications. (cdc.gov)
  • Elderly persons and persons with underlying health problems are at increased risk for complications of influenza. (cdc.gov)
Impact of influenza2
  • In Canada, two available measures can reduce the impact of influenza: immunoprophylaxis with inactivated (killed-virus) vaccine and chemoprophylaxis or therapy with influenza-specific antiviral drugs. (canada.ca)
  • Immunization is the most effective means to reduce the impact of influenza. (canada.ca)
Secondary bacterial pneumonia1
  • More severe illness can result if either primary influenza pneumonia or secondary bacterial pneumonia occurs. (cdc.gov)
20232
  • 4 All Phase 3 COVID-19 vaccine trials are ongoing and not due to conclude until late 2022/early 2023. (mittval.is)
  • Comput Methods Programs Biomed , 2023 Jul 28;241:107733. (google.com)
Immunization4
  • Data were obtained from a provincewide population-based immunization registry and laboratory-based influenza surveillance system. (cdc.gov)
  • However, the availability of a provincewide, population-based immunization registry and laboratory-based influenza surveillance system provided a unique opportunity to investigate these issues in Manitoba. (cdc.gov)
  • At 1 week after a third immunization, 16 participants demonstrated a median threefold increase in neutralizing antibody responses, but no improvement was observed in T cell responses. (nature.com)
  • National influenza surveillance is coordinated through the Immunization and Respiratory Infections Division (IRID), Public Health Agency of Canada (PHAC). (canada.ca)
Illness2
  • [1-5] Aspirin and other salicylate-containing medications are contraindicated for children and adolescents with influenza-like illness, as their use during influenza infection has been associated with the development of Reye syndrome. (cdc.gov)
  • There is low certainty evidence from nine trials (3507 participants) that wearing a mask may make little or no difference to the outcome of influenza‐like illness (ILI) compared to not wearing a mask (risk ratio (RR) 0.99, 95% confidence interval (CI) 0.82 to 1.18. (drrobertyoung.com)
Avian influenza1
  • This statement contains new information on human and avian influenza epidemiology. (canada.ca)
Patients with solid tumors1
  • In this study, we compared immune responses to the BNT162b2 mRNA Coronavirus Disease 2019 vaccine in patients with solid tumors ( n = 53) who were on active cytotoxic anti-cancer therapy to a control cohort of participants without cancer ( n = 50). (nature.com)
Systemic2
Dose7
  • An additional dose of the vaccine should not be given to those who have experienced a severe hypersensitivity reaction to a previous dose of Vaxzevria. (medicines.org.uk)
  • In clinical trials, single-dose baloxavir is safe and effective in treating patients with uncomplicated influenza. (medscape.com)
  • Liver injury was observed after both, mRNA and vector-based vaccines, while time from vaccine administration to symptom onset ranged between 4 days after the first dose to 6 weeks after the second dose. (alecomm.com)
  • Here, we describe the case of a 52-year-old male presenting with acute mixed hepatocellular/cholestatic hepatitis after the first dose of BNT162b2 mRNA vaccine and severe hepatitis after the second dose. (alecomm.com)
  • Prospective assessment of humoral and cellular immune responses to a 3rd COVID-19 mRNA vaccine dose among immunocompromised individuals. (amedeo.com)
  • Protein dose-sparing effect of AS01B adjuvant in a randomized preventive HIV vaccine trial of ALVAC-HIV (vCP2438) and adjuvanted bivalent subtype C gp120. (amedeo.com)
  • The booster dose elicited comparable bAb concentrations between CPs and HCWs, regardless of the primary vaccine type. (e-crt.org)
Effectiveness2
  • BACKGROUND: Accurate determination of COVID-19 vaccination status is necessary to produce reliable COVID-19 vaccine effectiveness (VE) estimates. (bvsalud.org)
  • Limited data exist for clinical vaccine effectiveness, but it has been estimated at about 85% after a full vaccination course. (sa.gov.au)
Antibodies3
  • Vaccine-induced antibodies were determined by ELISA. (alecomm.com)
  • SARS-CoV-2 mRNA vaccines induce greater complement activation and decreased viremia and Nef antibodies in men with HIV-1. (amedeo.com)
  • Spike-specific binding antibodies (bAbs) in all participants and neutralizing antibodies (nAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) wild-type, Delta, and Omicron variants in CPs were analyzed and presented as the geometric mean titer. (e-crt.org)
Seasonal3
  • Because influenza seasons are unpredictable and often fluctuate in length and severity, the overall burden seasonal influenza varies from year to year. (cdc.gov)
  • Because of this ongoing antigenic drift, seasonal influenza virus vaccine formulations are reviewed by the WHO bi-annually. (health.govt.nz)
  • 3005 participants)…the pooled results of randomised trials did not show a clear reduction in respiratory viral infection with the use of medical/surgical masks during seasonal influenza. (drrobertyoung.com)
Moderna1
Meningococcal2
Antigenic1
  • The antigenic components of the influenza vaccine have been updated for the 2007-2008 season. (canada.ca)
Vaccination history2
Subtypes1
Hepatitis1
  • Notably, hepatitis severity correlated longitudinally with an activated cytotoxic phenotype of peripheral SARS-CoV-2-specific, but not EBV-specific CD8+ T cells or vaccine-induced immunoglobulins. (alecomm.com)
Immunity1
  • In this study, balance training using body-weight is a good method of home-based physical activity for the elderly, because it not only improves immunity by increasing physical fitness but also prevents frequent falls by increasing the balance ability of the lower extremities. (ajkinesiol.org)
Immunogenicity2
  • We investigated the immunogenicity and safety of an adjuvanted recombinant zoster vaccine (RZV) in renal transplant (RT) recipients ≥18 years of age receiving daily immunosuppressive therapy. (scienceopen.com)
  • We aimed to assess the humoral response to and reactogenicity of coronavirus disease 2019 (COVID-19) vaccination according to the vaccine type and to analyze factors associated with immunogenicity in actively treated solid cancer patients (CPs). (e-crt.org)
Clinical2
  • These results suggest that early and aggressive treatment action should be taken in patients with a high clinical suspicion of severe influenza infection. (medscape.com)
  • Dr Mike Yeadon, joint applicant on this request, asserts that claims calling the Covid-19 injections a 'vaccine is public manipulation and misrepresentation of clinical treatment. (mittval.is)
Infection9
  • Although responses to vaccines are impaired in these populations, immunizations remain an important component of preventative care due to their favorable safety profiles and the high rate of infection in these patients. (scienceopen.com)
  • Influenza vaccination also must be encouraged to prevent the infection. (medscape.com)
  • 16 y who have symptoms of influenza infection or colds, aspirin is not recommended because of an association with Reye syndrome . (medscape.com)
  • 1 ] Influenza C is associated with mild cases of upper respiratory infection. (health.govt.nz)
  • Therefore, the presence of low copy number of HBoV, detected by molecular method, may indicate prolonged viral shedding or an asymptomatic infection. (datexis.com)
  • [ 10 ] For high-risk individuals, these recommendations remain to avoid infection from COVID-19 and other infections (eg, RSV, influenza). (medscape.com)
  • infection with ebola virus causes a severe disease accompanied by high mortality rates, and there are no licensed vaccines or therapies available for human use. (liverpool.ac.uk)
  • filovirus vaccine research efforts still need to determine the roles of humoral and cell-mediated immune responses in protection from ebola virus infection. (liverpool.ac.uk)
  • Still, that's enough time for the vaccines to train the body to recognize and attack the virus in the event of infection. (biopharmadive.com)
Prevention1
  • As with other diseases, prevention of influenza is the most effective strategy. (medscape.com)
Severity1
  • In immunosuppressed individuals, the presentation can be atypical and vary in severity depending on degree of immunosuppression and host immune response. (scienceopen.com)
20191
  • Participants Over 5500 solid organ transplant recipients have been enrolled in all six Swiss transplant centres by end of 2019, around three-quarter of them for kidney and liver transplants. (bmj.com)
Fever2
  • There may be a small increased risk of fever and febrile convulsions with concomitant delivery of PCV13 and influenza vaccine in children aged 6 months to under 5 years. (health.govt.nz)
  • Combo Vaccine Raises Risk of Fever-Related Seizure. (blogspot.com)
Doses4
  • Methods In this phase 3, randomized (1:1), observer-blind, multicenter trial, RT recipients were enrolled and received 2 doses of RZV or placebo 1-2 months (M) apart 4-18M posttransplant. (scienceopen.com)
  • Children aged under 9 years who have not previously received influenza vaccine require 2 doses 4 weeks apart (funded for children with eligible conditions). (health.govt.nz)
  • We compared the number of mRNA COVID-19 vaccine doses identified by each of these sources to assess agreement as well as differences in VE estimates using vaccination data from each individual source and vaccination data adjudicated from all sources combined. (bvsalud.org)
  • Numbers of COVID-19 vaccine doses identified by IIS, EMR, and self-report were compared in kappa agreement analyses. (bvsalud.org)
Recommendations2
  • Recommendations for use and other information set out herein may differ from that set out in the product monograph(s)/leaflet(s) of the Canadian manufacturer(s) of the vaccine(s). (canada.ca)
  • This year, recommendations for routine influenza vaccine receipt have been expanded to include all pregnant women. (canada.ca)
Immune response1
Illnesses2
  • 473 QuickStats care providers are aware of recommended testing methods for clinically compatible illnesses. (cdc.gov)
  • Unlike other common respiratory illnesses, influenza can cause severe malaise lasting several days. (cdc.gov)
Vector-based1
  • The participants had no history of previous COVID-19 and received either mRNA-based or adenovirus vector-based (AdV) vaccines as the primary series. (e-crt.org)
Occurs1
  • Person-to-person transmission of influenza virus occurs through droplets from the respiratory tract that are spread by direct contact, through coughing or sneezing, or by hands contaminated with respiratory secretions. (canada.ca)